- Morgan Stanley analyst Elizabeth Porter affirmed ZoomInfo Technologies Inc (NASDAQ:ZI) with an Overweight rating and a price target of $66.
- Porter’s deep dive analysis increases confidence that ZoomInfo can durably grow revenue 30%+ over the next three years while also generating 40%+ operating margins, resulting in one of the most efficient unit economics in the SaaS peer group.
- She notes that sustaining 30%+ revenue CAGR through 2024 is supported by 1) a significant greenfield opportunity with low single-digit penetration, 2) uplift in annualized contract value (ACV) as users adopt Advanced Functionality workflows, and 3) improving retention from stickier software adoption beyond company and contact data.
- The analyst points out that sustainable topline growth combined with a mid-40% operating margin yields a strong FCF growth engine, providing scale to enable investment ahead of peers.
- While shares trade at a premium EV/S/G multiple, she believes this does not correctly consider the best-in-class profitability and sees shares trading at a discount on EV/FCF/G and PEG.
- Her price target reflects a premium to the SaaS group average, given a unique combination of growth and profitability with a Rule of 40 at 80%+, well ahead of the ~25% SaaS average.
- Price Target: ZI shares traded higher by 0.72% at $46.21 on the last check Wednesday.
Older Patients Are Choosing Cannabis To Treat Chronic Pain, Arthritis, Anxiety And Insomnia, New Study Shows
Older patients comprise a growing subset of medical cannabis patients, according to a new study. Titled Age-related Patterns of Medical Cannabis Use: A Survey of Authorized Patients in Canada, the new scientific publication presented the consumption trends observed in patients and the self-reported impacts of medical cannabis in alleviating the patients' primary symptoms. Tilray Medical, a division of Tilray Brands, Inc. is behind the study which is derived from the Canadian Cannabis Patient Survey (CCPS) 2021, which included 2,697 patients. The researchers focused primarily on older patients with a mean age of 54.3. Patients with chronic pain (27.8%), arthritis (14.9%) and anxiety (9%) were the most numerous among those seeking cannabis to treat their primary illnesses. Pain was the most common primary symptom for which patients use medical cannabis, followed by anxiety and insomnia/sleep disorder.
